Yüklüyor......
A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers
BACKGROUND: RET rearrangements are found in 1–2% of non-small cell lung cancers. Cabozantinib is a multikinase RET inhibitor that produced a 10% response rate in unselected patients with lung cancers. To evaluate the activity of cabozantinib in patients with RET-rearranged lung cancers, we conducted...
Kaydedildi:
| Yayımlandı: | Lancet Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5143197/ https://ncbi.nlm.nih.gov/pubmed/27825636 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30562-9 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|